Dealing with peeing problems (urinary incontinence)
This page will provide information on how to access support if you have problems with your peeing (urinary incontinence).
Some treatments for prostate cancer will cause problems with peeing. This may be:

Leaking or dribbling pee

Problems passing pee.
Watch this short animation about getting support for peeing problems after treatment for prostate cancer.
The animation describes the experience of a man who has had surgery. However, the information is also relevant for people who have had other treatments.
The National Institute for Health and Care Excellence (NICE) provides guidance on:
Learn more about NICE and what they do by visiting their website (link will open in a new tab).


Many areas will have an NHS-run continence service. These are often staffed by continence nurse specialists and continence advisors.
They will ask you about the
They will then be able to offer advice and treatment plans suitable for you.
This may include:
They can work with your GP to prescribe medication or devices.
They can link with other healthcare professionals if you need more specialist treatment.
In men, the pelvic floor goes from the tailbone (coccyx) to the pubic bone. It supports the bladder and bowel.
The tube that brings pee from your bladder to the outside is called the urethra. The urethra and the rectum pass through the pelvic floor muscles.

The pelvic floor is important in:
Pelvic floor exercises can help to strengthen your pelvic floor muscles.

You may not be able to access free continence products or services in all areas. Ask your GP for more information.
You can ask them:
You can find their contact details on the NHS England website.

The toolkit is an information resource for people affected by prostate cancer. The development has been funded through an educational grant from Advanced Accelerator Applications (A Novartis Company).

Always get advice from your healthcare team before trying new exercises.

The toolkit is an information resource for people affected by prostate cancer. The development has been funded through an educational grant from Advanced Accelerator Applications (A Novartis Company).